This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；
Male or female, age ≥12 years old;
Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);
Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);
Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.